Orbus Therapeutics Inc., established in 2018, is a biopharmaceutical company dedicated to developing innovative therapies for patients with serious and life-threatening diseases. With a focus on rare diseases, Orbus leverages its expertise in protein engineering and manufacturing to create transformative treatments.

The company's mission is to improve the lives of patients and their families by delivering high-quality, affordable therapies. By combining cutting-edge science with a patient-centric approach, Orbus Therapeutics is committed to making a meaningful difference in the lives of those affected by rare diseases.

Orbus Therapeutics' Pipeline
Orbus Therapeutics has a robust pipeline of product candidates, each targeting a specific unmet medical need. The company's pipeline is diverse, encompassing various therapeutic areas and stages of development.

Some of the key programs in Orbus Therapeutics' pipeline include:
- OT-101, an enzyme replacement therapy for Fabry disease, currently in Phase 3 clinical trials.
- OT-201, a potential treatment for Gaucher disease, currently in Phase 2 trials.
- OT-301, a novel therapy for Pompe disease, which is in the preclinical stage.

Fabry Disease and OT-101
Fabry disease is a rare, genetic disorder caused by the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells. This buildup can lead to various symptoms, including pain, kidney damage, and heart problems. OT-101 is an enzyme replacement therapy designed to address the underlying cause of Fabry disease.
Clinical trials have shown that OT-101 can effectively reduce the accumulation of globotriaosylceramide in various tissues, potentially slowing down the progression of the disease and improving patients' quality of life.

Gaucher Disease and OT-201
Gaucher disease is another rare, genetic disorder that affects the body's ability to break down certain fats. This leads to an accumulation of these fats in various organs, causing symptoms such as anemia, bone pain, and liver and spleen enlargement. OT-201 is an investigational therapy designed to target and reduce the buildup of these harmful fats.
Early clinical data suggest that OT-201 may improve symptoms and slow down the progression of Gaucher disease, offering hope to patients and their families.

Orbus Therapeutics' Approach to Rare Diseases
Orbus Therapeutics' approach to rare diseases is characterized by a deep understanding of the underlying biology, a commitment to patient engagement, and a focus on developing therapies that can make a real difference in patients' lives.




















The company works closely with patient advocacy groups, healthcare professionals, and researchers to ensure that its therapies address the most pressing unmet needs in rare diseases. By combining this insights-driven approach with its scientific expertise, Orbus Therapeutics is well-positioned to deliver innovative treatments for patients with rare diseases.
Patient Engagement
Orbus Therapeutics places a strong emphasis on patient engagement, ensuring that the patient voice is integral to its drug development process. The company works closely with patient advocacy groups to understand the unique challenges and needs of patients with rare diseases, incorporating this feedback into its clinical trial designs and therapeutic approaches.
By prioritizing patient engagement, Orbus Therapeutics aims to create therapies that not only address the underlying biology of rare diseases but also meet the practical needs and preferences of patients.
Collaboration and Partnerships
Orbus Therapeutics recognizes the importance of collaboration and partnerships in accelerating the development of innovative therapies for rare diseases. The company has established strategic partnerships with leading academic institutions, biotechnology companies, and pharmaceutical organizations to advance its pipeline and expand its reach.
Through these collaborations, Orbus Therapeutics can leverage the expertise and resources of its partners, enhancing its ability to bring transformative therapies to patients with rare diseases.
As Orbus Therapeutics continues to grow and advance its pipeline, the company remains steadfast in its commitment to improving the lives of patients with rare diseases. By combining scientific innovation with a deep understanding of patient needs, Orbus Therapeutics is poised to make a lasting impact on the rare disease landscape.